BiotechTube

Dose A VTX958 + Dose B VTX958 + Placebo

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psoriatic Arthritis

Conditions

Psoriatic Arthritis

Trial Timeline

Jan 31, 2023 → Jan 2, 2024

NCT ID
NCT05715125

About Dose A VTX958 + Dose B VTX958 + Placebo

Dose A VTX958 + Dose B VTX958 + Placebo is a phase 2 stage product being developed by Ventyx Biosciences for Psoriatic Arthritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT05715125. Target conditions include Psoriatic Arthritis.

What happened to similar drugs?

10 of 20 similar drugs in Psoriatic Arthritis were approved

Approved (10) Terminated (0) Active (10)
✅Ixekizumab + AdalimumabEli LillyApproved
✅TirzepatideEli LillyApproved
✅GuselkumabJohnson & JohnsonApproved
✅methotrexate (MTX) + adalimumab (ADA)AbbVieApproved
✅Upadacitinib 15 MG [Rinvoq] + PlaceboAbbVieApproved
✅Secukinumab 300 mg + Secukinumab 150 mgNovartisApproved
✅ApremilastAmgenApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05715125Phase 2Terminated

Competing Products

20 competing products in Psoriatic Arthritis

See all competitors
ProductCompanyStageHype Score
SonelokimabMoonLake ImmunotherapeuticsPhase 3
41
Sonelokimab + Placebo + AdalimumabMoonLake ImmunotherapeuticsPhase 2
29
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
38
Sonelokimab + Placebo + RisankizumabMoonLake ImmunotherapeuticsPhase 3
41
Ixekizumab + PlaceboEli LillyPhase 3
40
Ixekizumab + TirzepatideEli LillyPre-clinical
33
Ixekizumab + TirzepatideEli LillyPhase 3
44
Ixekizumab + AdalimumabEli LillyApproved
43
Alefacept + Methotrexate + PlaceboAstellas PharmaPhase 2
35
SUNPG18_07 I (Tildrakizumab 200 mg) + SUNPG18_07 II (Tildrakizumab 100 mg)Sun PharmaceuticalPhase 2/3
38
TILD sub-cutaneous (SC) injectionSun PharmaceuticalPhase 3
44
SUNPG1623 I + SUNPG1623 II + SUNPG1623 III + SUNPG1623 IV + PLACEBOSun PharmaceuticalPhase 2
35
TILD + matching placebo injectionsSun PharmaceuticalPhase 3
40
TILD + matching placebo injectionsSun PharmaceuticalPhase 3
44
Ixekizumab + AdalimumabEli LillyPhase 3
44
TirzepatideEli LillyApproved
50
Placebo + Ixekizumab 80 mg Q4W + Ixekizumab 80 mg Q2WEli LillyPhase 3
40
GuselkumabJohnson & JohnsonApproved
50
RSS0393 ointment + RSS0393 ointment + RSS0393 ointment placeboJiangsu Hengrui MedicinePhase 2
42
SHR0302 tablets、Placebo + SHR0302 tablets、Placebo + PlaceboJiangsu Hengrui MedicinePhase 3
36